Senexin B and SNX631 (Selective CDK8/19 inhibitors) have shown synergistic interactions with lapatinib and trastuzumab in a group of HER2+ breast cancer cell lines, overcoming and preventing cell resistance to HER2-targeted drugs. This evidence concerns the gene CDK8 and breast carcinoma.